Current Vemurafenib News and Events

Current Vemurafenib News and Events, Vemurafenib News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 2 | 77 Results
Ludwig Cancer Research study reveals how ecDNA forms and drives cancer drug resistance
Researchers led by Ludwig San Diego Member Don Cleveland and Peter Campbell of the Sanger Center have solved the mystery of how free-floating circular DNA fragments, which are almost exclusively found in cancer cells, drive gene amplification to generate drug resistance in cancer. (2020-12-23)

Triple chemotherapy combination improves metastatic colorectal cancer outcomes
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination -- of irinotecan, cetuximab, and vemurafenib -- is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab. (2020-12-23)

Blocking a survival mechanism could tackle melanoma treatment resistance
The effectiveness of current treatments for melanoma, the deadliest form of skin cancer, could be improved by using approaches that wipe out the 'survival system' of cancer cells according to a study published in Nature Communications today. Researchers from the Babraham Institute, AstraZeneca and the Cancer Research UK Cambridge Centre have demonstrated an approach, used in parallel with existing treatments, which is effective at triggering tumor cell death and delaying treatment resistance. (2019-11-14)

Researchers identify compounds that starve melanoma cancer cells of energy
Researchers have found a possible counterpunch to the drug resistance of melanoma, the most dangerous form of skin cancer. (2019-06-18)

Combo T cell and targeted therapy strategy for resistant melanoma with BRAF mutation
Collaborative research by The Wistar Institute and Moffitt Cancer Center has demonstrated that BRAF targeted therapies render resistant melanoma more sensitive to the attack of killer T cells. (2019-02-14)

Melanoma: dabrafenib and trametinib have added benefit
This combination showed advantages in survival and recurrence. An added benefit was not proven for another combination used in advanced disease. (2019-01-08)

Combining three treatment strategies may significantly improve melanoma treatment
A study by a team led by a Massachusetts General Hospital investigator finds evidence that combining three advanced treatment strategies for malignant melanoma -- molecular targeted therapy, immune checkpoint blockade and the use of tumor-targeting viruses -- may markedly improve outcomes. (2018-12-12)

Understanding epilepsy in pediatric tumors
A KAIST research team led by Professor Jeong Ho Lee of the Graduate School of Medical Science and Engineering has recently identified a neuronal BRAF somatic mutation that causes intrinsic epileptogenicity in pediatric brain tumors. (2018-09-18)

Drug combination targeting HSP90 and BRAF is safe and effective in advanced melanoma
A team of researchers at Moffitt Cancer Center have been working to learn more about how melanoma becomes resistant to BRAF inhibitors in order to develop new treatment strategies. They tested whether a drug targeting heat shock protein 90 (HSP90) combined with the BRAF inhibitor vemurafenib could be a safe and potentially effective strategy to treat patients with melanoma. Their study was published online ahead of print in Clinical Cancer Research. (2018-04-19)

Joint supplement speeds melanoma cell growth
Chondroitin sulfate, a dietary supplement taken to strengthen joints, can speed the growth of a type of melanoma, according to experiments conducted in cell culture and mouse models. (2018-03-15)

Oncotarget: Researchers identify novel therapeutic strategy for drug-resistant thyroid cancers
New findings by a Harvard Medical School team suggest that palbociclib, a drug that is FDA-approved to treat advanced breast cancer, may be able to overcome vemurafenib resistance in PTC. (2017-10-18)

Combination targeted adjuvant therapy doubles relapse-free survival in stage III melanoma
Combination targeted adjuvant therapy with dabrafenib and trametinib doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to late-breaking results from the COMBI-AD trial presented today at the ESMO 2017 Congress in Madrid and published in the New England Journal of Medicine. (2017-09-11)

Compound shows promise in treating melanoma
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward creating a drug that can kill melanoma cancer cells without harming nearby healthy cells. (2017-07-26)

Adding vemurafenib doubles progression-free survival in BRAF metastatic colorectal cancer
Clinical trial results presented in an oral abstract session 3:00pm Monday, June 5 at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 shows promising results for the addition of vemurafenib (anti-BRAF) to treatment with cetuximab and irinotecan (anti-EGFR) in patients with metastatic colorectal cancer that have a BRAF V600E mutation. (2017-06-05)

Genes associated with Erdheim-Chester disease also linked to cancer
Newly identified genes associated with Erdheim-Chester disease (ECD), an ultra-rare disease, are also linked to cancer, according to a new study by NHGRI researchers. Thus, ECD should be considered a type of cancer and treated by oncologists. A new clinical trial -- enrolling ECD patients now -- will test the use of the drugs dabrafenib and trametinib. (2017-03-31)

New driver, target in advanced mucosal melanoma
A University of Colorado Cancer Center study published March 15, 2017, in the journal Melanoma Research uses the unique resource of over 600 melanoma samples collected at the university to demonstrate, for the first time, novel mutations involved in mucosal melanoma, paving the way for therapies to treat this overlooked subtype. (2017-03-15)

Malaria drug successfully treats 26-year-old brain cancer patient
University of Colorado Cancer Center study published in eLife shows anti-authophagy drug chloroquine may be unique way to resensitize some cancer patients to treatment. (2017-01-17)

New colorectal cancer targeted therapy combination shows promise
New SWOG study results show significantly better outcomes for patients with a treatment-resistant form of metastatic colorectal cancer when the BRAF inhibitor vemurafenib is added to a standard treatment. The findings, for the first time, point at an effective treatment for this deadly type of cancer. (2017-01-17)

Nivolumab plus ipilimumab in melanoma: Added benefit in certain patients
Treatment-naive patients with BRAF V600 mutation-negative tumor survive longer. This advantage depends on sex, however. And severe side effects are more common. (2016-10-06)

Drug targeting BRAF mutation slows thyroid cancer, too
Researchers from Penn Medicine and other institutions found that treating metastatic thyroid cancer patients harboring a BRAF mutation with the targeted therapy vemurafenib -- originally approved for melanoma patients with the mutation -- showed promising anti-tumor activity in a third of patients. The results were published in this week's Lancet Oncology. (2016-07-22)

Cobimetinib in advanced melanoma with BRAF V600 mutation: Added benefit now considerable
Further advantages of the drug in comparison with the comparator therapy resulted from the analyses subsequently submitted by the drug manufacturer in the commenting procedure. (2016-06-03)

Current cancer drug discovery method flawed: Study
The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers report May 2 in Nature Methods. The findings cast doubt on methods used by the entire scientific enterprise and pharmaceutical industry to discover new cancer drugs. The researchers have developed a new metric to evaluate a compound's effect on cell proliferation -- called the DIP (drug-induced proliferation) rate -- that overcomes the flawed bias in the traditional method. (2016-05-02)

New tool mines whole-exome sequencing data to match cancer with best drug
New tool interprets raw data of whole exome tumor sequencing to match cancer's unique genetics with FDA-approved targeted treatments. (2016-03-29)

Cobimetinib in melanoma with BRAF V600 mutation: Indication of minor added benefit
Negative effects in several patient-relevant outcomes resulted in a downgrading of the extent of the positive effects. (2016-03-18)

Dabrafenib/trametinib: Considerable added benefit for men with advanced melanoma
Based on the study data subsequently submitted, there is now an indication of considerable added benefit for men; there is still major added benefit for women. (2016-03-18)

HIV drug could stop skin cancer becoming drug-resistant
An HIV drug could stop one of the early changes in skin cancer cells that leads to them becoming resistant to treatment. (2016-03-14)

Dabrafenib/trametinib in advanced BRAF V600 mutated melanoma: Indication of added benefit
Dabrafenib (trade name: Tafinlar) has been approved since 2013 for the treatment of adults with advanced melanoma with a BRAF V600 mutation. (2016-01-13)

Scientists identify promising new melanoma drug
The first-in-class compound halts tumor growth by disrupting protein production. (2015-11-24)

Pembrolizumab in advanced melanoma: Added benefit for certain patients
Certain adults with pretreatment have fewer side effects under pembrolizumab. Treatment-naive patients without tumor mutation survive longer and have better social participation. (2015-11-23)

Massive screen of drug combinations may find treatment for resistant, BRAF-mutant melanoma
A team of Massachusetts General Hospital investigators has discovered a new combination of drugs that may be effective against one of the deadliest cancers, malignant melanoma. The combination -- pairing a drug targeted against mutations in the BRAF gene with a second drug that targets another important signaling pathway -- was discovered through one of the largest screens of cancer drug combinations conducted to date. (2015-10-26)

Nivolumab in melanoma: Added benefit in certain patients
Treatment-naive patients with BRAF V600 mutation-negative tumor have an advantage in overall survival. The drug manufacturer dossier contained no suitable data for further patient groups. (2015-10-20)

Combining 2 targeted therapies results in melanoma patients living significantly longer
Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone. (2015-09-27)

Memorial Sloan Kettering Cancer Center researchers publish landmark 'basket study'
Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated. (2015-08-20)

Melanoma mutation rewires cell metabolism
A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme. The finding points to possible strategies for countering resistance to existing drugs that target the B-raf V600E mutation, or potential alternatives to those drugs. It may also explain why the V600E mutation in particular is so common in melanomas. (2015-07-02)

Moffitt researchers discover mechanism leading to BRAF inhibitor resistance in melanoma
The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining cells adapt to treatment and become resistant. Moffitt Cancer Center researchers have discovered a novel mechanism that can lead melanoma cells to develop resistance to drugs that target the protein BRAF. (2015-06-19)

Melanoma, pediatric cancer and lymphoma dominate research from NYU Langone at ASCO 2015
NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center will have a high profile at the 51st Annual Meeting of the American Society for Clinical Oncology (ASCO), with researchers presenting close to 30 abstracts accepted for oral, poster and publication presentations. (2015-05-26)

Evidence grows that melanoma drugs benefit some lung cancer patients
A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference in Geneva, Switzerland. (2015-04-17)

UCSF-led study shows why some targeted cancer drugs lose effectiveness
A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers. (2015-02-09)

Next-gen melanoma drug, TAK-733, excels in lab tests
A University of Colorado Cancer Center study published online this week in the journal Molecular Cancer Therapeutics reports anti-cancer activity in 10 out of 11 patient tumor samples grown in mice and treated with the experimental drug TAK-733, a small molecule inhibitor of MEK1/2. (2014-11-11)

New data on combination treatments for melanoma
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. (2014-09-29)

Page 1 of 2 | 77 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.